Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lupin Ltd Board/Management Information 2025

May 15, 2025

61031_rns_2025-05-15_09ae165f-f8f0-4ec6-bab5-dccfaf72bb3d.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [79 x 93] intentionally omitted <==

May 15, 2025

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and ‘ ’ Disclosure Requirements) Regulations, 2015 ( Listing Regulations ).

Dear Sir/Madam,

We are pleased to enclose a Press Release as regards, appointment of Punita Lal as an Additional Director (NonExecutive, Independent) of the Company.

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Digitally signed by AMIT KUMAR GUPTA DN: c=IN, st=Maharashtra, 2.5.4.20=f72cf02f52d2a7e595b45b84659bdca28c8f26a939bb35 835a169f2a237229a3, postalCode=400705, street=C701 Shivdarshan CHS Ltd Sector16 Plot No5 Navi Mumbai, pseudonym=d3a468d0d03546efabffd2a7cb7aaaae, title=7875, serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d7 0287df6aad1994f0b522fa08a, o=Personal, cn=AMIT KUMAR GUPTA Date: 2025.05.15 16:45:12 +05'30'

AMIT KUMAR GUPTA

AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)

Encl: a/a.

LUPIN LIMITED

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Punita Lal Joins Lupin Board as Additional Director

Mumbai, Naples, May 15, 2025: Global pharma major Lupin Limited (Lupin) announced the appointment of Punita Lal as an Additional Director (Non-Executive, Independent) to its Board of Directors.

Punita has a distinguished career spanning over 35 years in strategy, marketing, and leadership across Asia, encompassing various geographies and industries. She has held senior positions at Coca-Cola in China and PepsiCo in India. She served as Managing Director & CEO of NourishCo, a joint venture between Tata Global Beverages and PepsiCo.

Following her executive tenure, Punita focused on consulting for SMEs, playing a significant role in fostering innovation. She is also a qualified leadership coach.

Punita has served on the boards of DBS Bank, Carlsberg A.S., Cipla, CEAT, and Entertainment Networks India. She has been recognized among India’s top 20 businesswomen by Business Today in 2006, and Corporate Woman of the Year by FICCI Women’s Organisation in 2009.

Punita’s academic credentials include a Bachelor of Arts (Honors) in Economics from St. Stephen’s College, Delhi, and an MBA from the Indian Institute of Management, Kolkata.

Manju D Gupta , Chairman, Lupin said, “We are delighted to welcome Punita to our board. Her vast experience and expertise will be instrumental in guiding Lupin’s strategic initiatives and strengthening our position in the global pharmaceutical industry.”

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact:

Rajalakshmi Azariah Vice President & Global Head – Corporate Communications, Lupin [email protected]

Page 1 of 1